Project Name: Regional Diagnostics Hub – Nuclear Medicine Physicist – Hull University Teaching NHS Hospital NHS Trust
Project Summary:
CW Partner, in collaboration with Novartis, is launching a new Collaborative Working Project aimed at addressing workforce limitations within the Nuclear Medicine Physics department. This initiative will enable the introduction of a Gallium service and Ga-PET imaging capabilities, positioning CW Partner as a Regional Diagnostics Hub.
The project is designed to tackle regional inequities in access to diagnostic services, enhance patient care across the region, and prepare CW Partner for clinical trials and therapy readiness.
The expected outcomes of this CWP are:
- Expanded Capacity and Efficiency in Nuclear Medicine
The new role will support both Gallium and wider Nuclear Medicine services helping to reduce referral-to-imaging lead times, and improve imaging accuracy.
- Reduction in Health Inequalities
By providing access to imaging services closer to patients’ homes, the project will eliminate the need for long-distance travel prior to treatment, improving equity of access.
- Therapy and Trials Readiness
The new imaging capabilities will position CW Partner to participate in future clinical trials and serve as a checkpoint for delivering molecular radiotherapy treatments.
The project is structured around 14 milestones, including recruitment, baseline data collection, regular activity reporting, and sustainability.
Expected Benefits:
Patient Benefits:
Care closer to home, reduction in travel time and distance, and more equitable access to Ga-PET scanning facilities.
Reduction in time from referral to imaging and results availability.
CW Partner Benefits:
Improved imaging accuracy due to switch in scanning capabilities.
Improved overall quality of care and ensuring greater equity of access to diagnostics for eligible patients.
Maintaining standards for high-calibre imaging centres and developing capabilities for Trials/MRT Therapy readiness.
External patient referrals received for patient diagnostics.
Novartis Benefits:
Increased access to Ga-PET imaging for patients undergoing Nuclear Medicine Therapies (which may include Novartis Therapies).
Expected increase in access for Nuclear Medicine Therapies (which may include Novartis Therapies).
Improved insights into Nuclear Medicine Diagnostics pathways.
Start Date & Duration:
Start date: March 2026
Duration: 33 months
FA-11572152 | April 2026